General Information of Drug (ID: DMP84HB)

Drug Name
JNJ-40411813
Synonyms
JNJ-40411813; 1127498-03-6; ADX-71149; JNJ40411813; JNJ 40411813; 2(1H)-Pyridinone, 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-; 1-butyl-3-chloro-4-(4-phenylpiperidin-1-yl)pyridin-2-one; CHEMBL3337527; 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone; 1-butyl-3-chloro-4-(4-phenylpiperidin-1-yl)pyridin-2(1H)-one; 612BYT76F3; 1'-Butyl-3'-chloro-4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4']bipyridinyl-2'-one; 1-butyl-3-chloranyl-4-(4-phenylpiperidin-1-yl)pyridin-2-one; 1'-Butyl-3'-chloro-4-phenyl-3,4,5,6-tetrahydro-2H,1'H-(1,4')bipyridinyl-2'-one; HYOGJHCDLQSAHX-UHFFFAOYSA-N; ADX71149; HZR; ADX 71149; UNII-612BYT76F3; GTPL8946; SCHEMBL1035416; DTXSID601032323; BCP23709; CVB49803; EX-A2902; BDBM50051408; CS-3357; DB12059; SB16990; ADX-71149ADX-71149; NCGC00485897-01; AC-35478; HY-15748; MS-25297; FT-0752754; F85059; JNJ-40411813; ADX-71149; A894527; Q27895859; 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-2(1H)-Pyridinone; 1'-Butyl-3'-chloro-4-phenyl-3,4,5,6-tetrahydro-2H,1 'H-[1,4']bipyridinyl-2'-one; 1'-Butyl-3'-chloro-4-phenyl-3,4,5,6-tetrahydro-2H,1'H-[1,4]bipyridinyl-2'-one; JNJ-40411813; JNJ 40411813; ADX71149; ADX 71149; ADX-71149
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Phase 2 [1]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C20H25ClN2O
Canonical SMILES
CCCCN1C=CC(=C(C1=O)Cl)N2CCC(CC2)C3=CC=CC=C3
InChI
InChI=1S/C20H25ClN2O/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17H,2-3,9-10,12-14H2,1H3
InChIKey
HYOGJHCDLQSAHX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
25195461
ChEBI ID
CHEMBL3337527
TTD ID
D2JF0S
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

References

1 ClinicalTrials.gov (NCT04836559) A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-40411813 as Adjunctive Therapy in Subjects With Focal Onset Seizures With Suboptimal Response to Levetiracetam or Brivaracetam. U.S.National Institutes of Health.